A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants with Previously Untreated Multiple Myeloma The primary objective is to determine if the addition of daratumumab to VMP will prolong PFS compared with VMP.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease Estudio para Valorar la Seguridad del Tratamiento a Largo Plazo de Siltuximab en Sujetos con Enfermedad de Castleman Multicéntrica The primary objective is to evaluate the long-term safety of siltuximab in subjects with MCD. El objetivo principal es evaluar la seguridad a largo plazo del siltuximab en pacientes con enfermed...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to understand the effect of Niraparib in men with end-stage PCA+ To assess the efficacy of niraparib in subjects with measurable mCRPC and DNA-repair anomalies.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Daratumumab (HuMax-CD38) safety study in multiple myeloma – Open label, dose-escalation followed by open label, single-arm study To establish the safety profile of HuMax-CD38 when given as monotherapy in patients with multiple myeloma relapsed or refractory to at least 2 different cytoreductive therapies and without further est...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study The primary efficacy endpoint to be evaluated for registration in the United States and the Rest of the World is the percent reduction from the pretreatment baseline phase in seizure frequency (averag...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

PROTEA: A clinical trial comparing the efficacy of darunavir/ritonavir 800/100 mg monotherapy versus a triple combination therapy containing darunavir/ritonavir 800/100 mg and 2 nucleoside/nucleotide reverse transcriptase inhibitors in patients with undetectable plasma HIV-1 RNA on current treatment The primary objective is to demonstrate non-inferiority in terms of the percentage of subjects who have plasma HIV-1 RNA levels <50 copies/mL after 48 weeks of follow-up after switching to DRV/rtv mon...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Long-term Safety and Efficacy of Sirukumab in Participants with RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antir...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety Trial of JNJ-54861911 in Participants who are Asymptomatic At Risk for Developing Alzheimer’s Dementia The primary objective of this study is to determine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Precl...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thrombocytopenia in Subjects with Non-Small Cell Lung Cancer Receiving Gemcitabine and Either Carboplatin or Cisplatin To evaluate the efficacy of RWJ-800088 on the prevention of CIA in subjects with non-small cell lung cancer (NSCLC) receiving a 21-day chemotherapy regimen of gemcitabine and either carboplatin or cis...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome The ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome) Amendment INT-2 The primary objective of the study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular (CV) death, myocardial infarction (MI), or strok...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune